Physician profile
Steven B Siepser
NPI 1891756375
$7,330.13
in general payments reported to CMS, 2019-2025
31 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $331 · 2021: $593 · 2022: $2,357 · 2023: $858 · 2024: $1,819 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.43 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,383.54 | 2019-2025 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $1,328.22 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $795.94 | 2021-2025 | Rhopressa, Rocklatan, Hydrus Microstent |
| Harrow Eye, LLC | $434.42 | 2024-2025 | Vevye |
| Abbvie INC. | $287.16 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Glaukos Corporation | $281.05 | 2020-2023 | Idose Tr |
| Oyster Point Pharma, INC. | $270.77 | 2022-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $252.26 | 2019-2024 | |
| Dompe US, INC. | $251.24 | 2019-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $246.59 | 2019-2025 | Cequa |
| Allergan, INC. | $240.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $161.34 | 2019-2023 | |
| New World Medical,INC. | $159.26 | 2022 | |
| Horizon Therapeutics Plc | $155.93 | 2021-2023 | Tepezza |
| Glaxosmithkline, LLC. | $153.41 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $141.63 | 2022-2024 | Miebo, Envista Mx60 Iol, Crystalens Accommodating Iol (At-52ao) |
| Omeros Corporation | $132.83 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.97 | 2019-2021 | |
| Beaver-Visitec International, INC. | $116.53 | 2021-2023 | |
| Kala Pharmaceuticals, INC. | $85.49 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $65.83 | 2023-2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Rxsight INC | $46.64 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Katena Products, INC. (Dba Corza Medical) | $35.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.25 | 2022 | |
| Shire North American Group INC | $34.18 | 2019 | |
| Amgen INC. | $31.91 | 2025 | Tepezza |
| Alexion Pharmaceuticals, INC. | $22.03 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.53 | 2019 | |
| Ocular Therapeutix, INC. | $16.68 | 2019 | |
| Akorn Operating Company LLC | $15.38 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Siepser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.